Answers are grounded in this paper and cite their sources.
// Lorena Simón-Gracia 1 , Pablo Scodeller 1 , Sergio Salazar Fuentes 2 , Vanessa Gómez Vallejo 3 , Xabier Ríos 3 , Eneko San Sebastián 3 , Valeria Sidorenko 1 , Desirè Di Silvio 4 , Meina Suck 5, 6 , Federica De Lorenzi 5 , Larissa Yokota Rizzo 5 , Saskia von Stillfried 5 , Kalle Kilk 7 , Twan Lammers 5, 6 , Sergio E. Moya 4 and Tambet Teesalu 1, 8, 9 1 Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, 50411 Tartu, Estonia 2 Animal Unit, CIC Biomagune, 20009 Donostia, Spain 3 Laboratory of Radiochemistry, CIC Biomagune, 20009 Donostia, Spain 4 Soft Matter Laboratoy, CIC Biomagune, 20009 Donostia, Spain 5 Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany 6 Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, 7500 AE Enschede, The Netherlands 7 Department of Biochemistry, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, 50411, Estonia 8 Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92097, USA 9 Center for Nanomedicine, University of California Santa Barbara, Santa Barbara, California 93106, USA Correspondence to: Tambet Teesalu, email: tteesalu@sbpdiscovery.org Sergio E. Moya, email: smoya@cicbiomagune.es Lorena Simón-Gracia, email: Lorena.Simon.Gracia@ut.ee Keywords: PET; tumor-penetrating peptide; polymersomes; triple negative breast cancer; p32 Received: November 22, 2017 Accepted: February 10, 2018 Published: April 10, 2018 ABSTRACT Triple negative breast cancer (TNBC) is the deadliest form of breast cancer and its successful treatment critically depends on early diagnosis and therapy. The multi-compartment protein p32 is overexpressed and present at cell surfaces in a variety of tumors, including TNBC, specifically in the malignant cells and endothelial cells, and in macrophages localized in hypoxic areas of the tumor. Herein we used polyethylene glycol-polycaprolactone polymersomes that were affinity targeted with the p32-binding tumor penetrating peptide LinTT1 (AKRGARSTA) for imaging of TNBC lesions. A tyrosine residue was added to the peptide to allow for 124 I labeling and PET imaging. In a TNBC model in mice, systemic LinTT1-targeted polymersomes accumulated in early tumor lesions more than twice as efficiently as untargeted polymersomes with up to 20% ID/cc at 24 h after administration. The PET-imaging was very sensitive, allowing detection of tumors as small as ~20 mm 3 . Confocal imaging of tumor tissue sections revealed a high degree of vascular exit and stromal penetration of LinTT1-targeted polymersomes and co-localization with tumor-associated macrophages. Our studies show that systemic LinTT1-targeted polymersomes can be potentially used for precision-guided tumor imaging and treatment of TNBC.
No takes yet. Share an insight, caveat, or question.
Simón‐Gracia et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: